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Abstract Granule cell neuronopathy (GCN) is a rare JC
virus infection of the cerebellar granule cell neurons in
immunocompromised patients. On brain imaging, GCN is
characterized by cerebellar atrophy which can be accom-
panied by infratentorial white matter lesions. The objective
of this study is to investigate the prevalence of MRI find-
ings suggestive of GCN in a large natalizumab-associated
progressive multifocal leukoencephalopathy (PML) cohort.
MRI scans from before, at the time of, and during follow-
up after diagnosis of PML in 44 natalizumab-treated MS
patients, and a control group of 25 natalizumab-treated
non-PML MS patients were retrospectively reviewed for
imaging findings suggestive of GCN. To assess and
quantify the degree of cerebellar atrophy, we used a 4
grade rating scale. Three patients in the PML group showed
imaging findings suggestive of GCN and none in the
control group. In two of these PML patients, cerebellar
atrophy progressed from grade 0 at the time of diagnosis of
isolated supratentorial PML to grade 1 and 2 after 2.5 and
3 months, respectively, in the absence of infratentorial
white mater lesions. The third patient had grade 1 cere-
bellar atrophy before diagnosis of infra- and supratentorial
PML, and showed progression of cerebellar atrophy to
grade 2 in the 3 months following PML diagnosis. None of
the other eight patients with infratentorial PML lesions
developed cerebellar atrophy suggestive of GCN. Three
cases with imaging findings suggestive of GCN were
detected among 44 natalizumab-associated PML patients.
GCN may, therefore, be more common than previously
considered in natalizumab-associated PML patients.
Keywords Multiple sclerosis  Granule cell
neuronopathy  PML  Cerebellar atrophy  MRI
Introduction
Progressive multifocal leukoencephalopathy (PML) is a
lytic infection of astrocytes, oligodendrocytes and neurons
caused by the JC virus (JCV), leading to irreversible
demyelination and neuronal damage [1]. PML occurs almost
exclusively in immunosuppressed patients, and traditionally
PML was mainly observed in human immunodeficiency
virus (HIV)-infected patients and patients with hematologic
malignancies. However, in recent years PML has emerged as
a serious complication of immunosuppressive treatment. In
particular, PML associated with monoclonal antibody
treatment of autoimmune diseases has attracted major
attention. PML has been reported especially in association
with the use of natalizumab, a monoclonal antibody against
the a4-integrin adhesion molecule approved for the treat-
ment of active relapsing–remitting multiple sclerosis (MS)
[2, 3]. As of June 3, 2015, 566 PML cases have been reported
in more than 138,800 natalizumab-treated MS patients [4].
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In addition to PML affecting white matter and gray
matter cells leading to heterogeneous imaging findings [5],
JCV-associated diseases sparing white matter cells and
almost exclusively affecting gray matter cells have been
described, such as JCV encephalopathy involving the cor-
tical gray matter and granule cell neuronopathy (GCN) [6].
GCN is characterized by a JCV infection of the cerebellar
granule cell neurons causing neuronal loss and gliosis,
ultimately leading to cerebellar atrophy and cerebellar
neurological symptoms [7, 8]. Even though cerebellar
atrophy is the leading imaging sign in the vast majority of
GCN patients, the imaging features may be heterogeneous
and subtle. The progression of cerebellar atrophy can be
accompanied by white matter changes of the cerebellum
and sometimes in the brainstem [9]. Involvement of the
brainstem in GCN patients can result in linear white matter
hyperintensities in the pons similar to those seen in mul-
tiple system atrophy (MSA) and in some PML patients,
which coined the term ‘‘hot cross bun sign’’ [9–11]. GCN
has mostly been reported in immunocompromised HIV-
infected patients. Recently, GCN has been described in two
natalizumab-treated MS patients [12, 13]. GCN can
develop either as isolated JCV-associated disease or con-
comitant to PML [8, 14].
Histopathological data have demonstrated that granule
cell neurons are frequently infected in patients classified as
PML, even in the absence of lesions suggestive of PML in
the neighboring cerebellar white matter [15]. However, to
date it is unknown to what extent infection of granule cell
neurons leads to imaging signs of GCN in PML patients. In
contrast to PML which can be detected in asymptomatic
stages [16], GCN may escape early detection, especially in
MS patients as they may have different stages of cerebral
atrophy, both supra- and infratentorial, resulting from
neurodegeneration in MS [17]. Underdiagnosis may thus
easily occur, even in closely monitored patients like
natalizumab-associated PML patients according to recent
expert guidelines [18].
The aim of our study was to investigate the prevalence
of imaging findings suggestive of GCN in a large cohort of
natalizumab-associated PML patients. The second aim was
to investigate a possible link between PML manifestations
in the posterior fossa and the development of imaging
findings suggestive of GCN.
Patients and methods
Patient selection, and patient consent
This was a retrospective study, reviewing brain MRI scans
of natalizumab-associated PML patients for imaging find-
ings suggestive of GCN. A total of 61 patients were
included from two previously described datasets (17
patients from the Dutch–Belgian natalizumab-associated
PML cohort and 44 patients who were referred by other
institutions to our center for second opinion and research
purposes) [19, 20]. For this study, the following inclusion
criteria have been applied: (1) a diagnosis of natalizumab-
associated PML according to the American Academy of
Neurology (AAN) PML diagnostic criteria as definite,
probable or possible PML [21]. (2) Availability of a brain
MRI prior to, at the time of, and following PML diagnosis.
(3) Availability of multiple brain MRI sequences, including
at least T2 and/or fluid attenuated inversion recovery
(FLAIR) weighted and T1-weighted sequences. (4) Imag-
ing materials available in the Digital Imaging and Com-
munication in Medicine (DICOM 3) file format. Exclusion
criteria were: (1) insufficient follow-up MRIs (defined as
no follow-up MRI available more than 3 months after
diagnosis), to confidently determine the presence or
absence of imaging findings suggestive of GCN. (2) Poor
image quality impairing the assessment of cerebellar
atrophy (i.e., movement artefacts, bad repositioning, etc.).
We randomly selected a control group of 25 patients
from our local cohort of natalizumab-treated MS patients.
Inclusion criteria for the control group were: availability of
at least three serial brain MRIs during a follow-up period of
approximately 1 year, treatment with natalizumab during
the follow-up period without interruptions, at least 1 year
of natalizumab treatment at the start of the follow-up
period, and the absence of PML lesion development.
Written informed consent for the use of clinical and
imaging data for research and educational purposes was
obtained from all participants and the study was conducted
with adherence to the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments.
MRI protocols
The image acquisition parameters including pulse sequen-
ces, head coils and magnetic field strengths (1.5 and 3 T)
and parameters related to spatial resolution were hetero-
geneous and based on local MRI protocols as the imaging
data were collected from different centers. All patients had
T2/PD-weighted images and/or FLAIR images available,
and a T1-weighted sequence available.
Image analysis and interpretation
Two raters with expertise in diagnosis and treatment of
GCN and PML (MPW, MTW) analyzed all brain MR
images in consensus on a digital workstation. As cerebellar
atrophy is the main imaging finding in GCN, the reference
MRI scan prior to PML diagnosis (defined as baseline
scan), the MRI scan at diagnosis and the MRI scans during
650 J Neurol (2016) 263:649–656
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follow-up after PML diagnosis were analyzed with respect
to the degree of cerebellar atrophy [8, 9]. We assessed and
semi-quantified the extent of cerebellar atrophy based on a
four-grade visual rating scale: grade 0: no atrophy; grade 1:
dilated sulci; grade 2: loss of volume; grade 3: end-stage
atrophy. This rating scale was derived in a modified form
from visual rating scales for cortical atrophy assessment
[22, 23]. Only those patients in whom cerebellar atrophy
increased at least one grade at the time of, or after the onset
of PML, were considered suggestive of GCN because there
were not sufficient imaging studies available to assess the
possible development of GCN before the baseline scan.
Furthermore, we scored and classified the presence of
infratentorial and supratentorial PML lesions at the time of
PML diagnosis and during follow-up.
In the control group the same assessment and semi-
quantification of cerebellar atrophy was performed for all
MRI scans, at least three per patient, during the approxi-
mate follow-up period of 1 year (median follow-up:
13 months, range 11–15 months).
Results
Patients
Of the 61 collected natalizumab-associated PML patients,
44 met the inclusion criteria and were, therefore, included
in this study (all 17 patients from the Dutch–Belgian
natalizumab-associated PML cohort, and 27 patients who
were referred by other institutions to our center for second
opinion and research purposes). The demographic and
clinical information of these patients and of the control
group is presented in Table 1.
Baseline cerebellar atrophy
In 30 of the 44 patients in the PML group there was already a
certain degree of cerebellar atrophy present at baseline
(grade 0: 14 patients, grade 1: 24 patients, grade 2: 6 patients,
grade 3: 0 patients). Also in the control group the majority of
patients had pre-existing cerebellar atrophy (grade 0: 9
patients, grade 1: 13 patients, grade 2: 3 patients, grade 3: 0
patients). The degree of cerebellar atrophy of all study par-
ticipants at baseline is shown in Table 2.
Imaging findings suggestive of GCN and clinical
symptoms of cerebellar pathology
Three patients in the PML group developed cerebellar
atrophy or showed progressive cerebellar atrophy follow-
ing PML diagnosis. The first patient had no cerebellar
atrophy (grade 0) at the time of the diagnosis of supra-
tentorial PML. A grade 2 cerebellar atrophy was detected
at 3 months after PML diagnosis, without the occurrence of
new cerebellar T2/FLAIR hyperintense lesions (Fig. 1). At
PML diagnosis the patient presented with reduced ability to
use her left hand and an impaired tandem gait. Two to three
Table 1 Demographic and
clinical information of the study
participants
PML group, n = 43
Median (range)
Control group, n = 25
Median (range)
Gender (female/male), n (%) 30 (68.2)/14 (31.8) 18 (72)/7 (28)
Age (years) 43.5 (32–71) 44.6 (21–52)
Natalizumab treatment duration (doses) 35.0 (13–86) 35.9 (12.1–88.4)
Asymptomatic at diagnosis, n (%) 8 (18.2) n/a
Symptomatic at diagnosis, n (%) 36 (81.8) n/a
Solely supratentorial PML lesions 35 (79.5) n/a
Both supra- and infratentorial PML lesions 8 (18.2) n/a
Solely infratentorial PML lesions 1 (2.3) n/a
PML progressive multifocal leukoencephalopathy, n/a not applicable
Table 2 Degree of cerebellar
atrophy on brain MRI at
baseline
PML group, n = 44 (%) Control group, n = 25 (%)
Cerebellar atrophy grade 0 14 (31.8) 9 (36)
Cerebellar atrophy grade 1 24 (54.5) 13 (52)
Cerebellar atrophy grade 2 6 (13.6) 3 (12)
Cerebellar atrophy grade 3 0 (0) 0 (0)
Four-grade cerebellar atrophy rating scale: grade 0: no atrophy; grade 1: dilated sulci; grade 2: loss of
volume; grade 3: end-stage atrophy
J Neurol (2016) 263:649–656 651
123
Fig. 1 Axial fluid attenuated
inversion recovery (FLAIR)
images of patient 1 showing no
cerebellar atrophy at the time of
PML diagnosis (grade 0, a–c)
and grade 2 cerebellar atrophy
3 months later (d–f). Note the
bilateral dilated sulci (open
arrowhead) in image d and the
loss of cerebellar volume with
enlargement of the fourth
ventricle (closed arrowhead) in
image e
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weeks after PML diagnosis the patient developed ataxic
dysarthria and dysphagia, suggestive of cerebellar
pathology.
The second patient also had no cerebellar atrophy (grade
0) at the time of supratentorial PML diagnosis. However,
grade 1 cerebellar atrophy was detected at 2.5 months after
diagnosis, without new cerebellar T2/FLAIR hyperintense
lesions (Fig. 2). Clinical information on the patient’s
symptoms at the time of imaging could not be retrieved.
The third patient was diagnosed with a combination of
supra- and infratentorial PML. Before and at the time of
PML diagnosis a grade 1 cerebellar atrophy was present.
Cerebellar atrophy progressed to grade 2, as there was clear
loss of volume, at 3 months after diagnosis (Fig. 3). In
addition, the bilateral cerebellar white matter lesions had
increased in volume. At the time of PML diagnosis the
patient presented with mild ataxia of her right arm and sub-
acute slurred speech, suggestive of cerebellar pathology.
Six weeks later the patient clinically deteriorated with
severe ataxia, anarthria, visual loss and right-sided hemi-
paresis. These data are summarized in Table 3. In the other
8 patients with infratentorial PML lesions at the time of
PML diagnosis and during follow-up, neither development
nor progression of cerebellar atrophy was observed during
follow-up. None of the patients in the control group
showed any progression or development of cerebellar
atrophy during the follow-up period.
Discussion
Despite frequent MRI monitoring in natalizumab-associ-
ated PML patients, only two GCN cases associated with
natalizumab treatment have been reported to date [12, 13].
As the imaging signs of GCN can be difficult to interpret,
we hypothesized that this disease might be underdiagnosed
in natalizumab-associated PML patients. In our series of 44
PML patients we indeed found three patients who devel-
oped cerebellar atrophy, or showed progression of already
existing cerebellar atrophy, after PML diagnosis, suggest-
ing concomitant presence of GCN.
In the first two patients cerebellar atrophy developed after
a diagnosis of supratentorial PML, without the occurrence of
new cerebellar whitematter T2/FLAIR hyperintense lesions.
Thus, this GCN imaging characteristic coincided with the
manifestation of supratentorial PML, which in turn demon-
strates active replication of JCV in the CNS of these two
patients at that time. Therefore, we believe GCN is the most
likely cause for cerebellar atrophy in these patients. The
development of cerebellar symptoms in the first patient,
weeks after PML diagnosis, further supports the suspicion of
GCN in this patient. The third patient had pre-existing
cerebellar atrophy which progressed after diagnosis of both
supra- and infratentorial PML. One can debate whether the
increase of cerebellar atrophy was the result of GCN or
secondary to volume loss resulting from infratentorial PML
manifestations. However, as none of the other eight patients
with infratentorial PML developed cerebellar atrophy, we
feel that this latter explanation is less likely, strongly sug-
gesting GCN as the cause of the progression of the cerebellar
atrophy. The cerebellar symptoms that this patient experi-
enced could presumably be the result from both the new
infratentorial PML lesions, as well as the rapidly progressive
cerebellar atrophy.
MS pathology can also cause cerebellar atrophy, which
explains the frequent cerebellar atrophy even before the
occurrence of PML as seen in Table 2. However, the clear
and rapid development or increase of cerebellar atrophy
following PML diagnosis in our three GCN suspected
patients, seems more than one would expect from the
gradual neurodegeneration as seen in MS pathology.
Indeed, none of the 25 patients in the control group showed
any progression of cerebellar atrophy. The control group
consisted of patients very similar to the PML group in
terms of patient characteristics and was followed up for a
period of about 1 year, which is much longer than the
2–3 months in which the suspected GCN patients showed
progressive cerebellar atrophy.
Fig. 2 Axial fluid attenuated inversion recovery (FLAIR) images (a,
c) and coronal T1 post-contrast images (b, d) of patient 2 showing no
cerebellar atrophy at the time of PML diagnosis (grade 0, a, b) and
grade 1 cerebellar atrophy 2.5 months later (c, d). Note the bilateral
dilated sulci in image c and d (open arrowheads)
J Neurol (2016) 263:649–656 653
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The concomitant occurrence of GCN and PML has been
reported previously in PML patients unrelated to natal-
izumab [10, 13, 14, 24]. Some of those patients had
supratentorial PML and cerebellar atrophy, while others
were diagnosed with infratentorial PML and showed pro-
gressive cerebellar atrophy. Approximately two-thirds of
Fig. 3 Axial fluid attenuated
inversion recovery (FLAIR)
images (a, d), and sagittal
FLAIR images (b, c, e, f) of
patient 3 showing grade 1
cerebellar atrophy at the time of
PML diagnosis (a–c) and grade
2 cerebellar atrophy 3 months
later (d–f). There were already
bilateral dilated sulci at
diagnosis (open arrowhead).
However, there was clear loss of
cerebellar volume 3 months
later. Again, note the enlarged
fourth ventricle (closed
arrowheads). In addition, large
hyperintense lesions in the
cerebellar peduncles and
brainstem developed (diamond
arrowheads)
654 J Neurol (2016) 263:649–656
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the reported GCN cases in the literature show additional
white matter changes in the cerebellum [9].
It remains an interesting question whether GCN should
be classified as a distinct disease entity or a variant of PML
mainly affecting granule cells of the cerebellum. It has
been shown that GCN is associated with certain mutations
of the VP1 C terminus region of the JCV DNA. These JCV
GCN mutants specifically infect cerebellar granule cell
neurons and have been shown to have a disadvantage for
growth in CNS white matter compared to wild-type JCV
[25, 26]. In patients with both GCN and PML, coinfection
of JCV with a GCN mutation and wild-type JCV has been
shown [10]. Therefore, it is hypothesized that, at least in
some cases with concomitant GCN and PML, wild-type
JCV is responsible for the PML phenotype and JCV with
VP1 mutations for the GCN phenotype [10].
Our study has several limitations. First, unfortunately
there were no histopathological data available which could
confirm our suspicion of GCN in the three suspected patients
by showing infection of the granule cell neurons. Second, we
were unable to recover CSF from the time of PML diagnosis
of the three suspected GCN patients to identify possible JCV
VP1 mutations. Finally, in most patients there was only one
baseline scan present prior to PML diagnosis. This and the
lack of JCV testing in CSF prior to the baseline scan pre-
cluded our ability to identify patients who had developed
GCN prior to the baseline scan. Parameters related to image
acquisition, in particular differences of pulse sequences (e.g.,
2D versus 3D acquisition) and/or MR systems (e.g., 1.5
versus 3 T), might result in subtle differences in the visual
appearance of cerebellar atrophy possibly leading to false-
positive or false-negative results regarding the degree of
cerebellar atrophy. We, therefore, confirmed any develop-
ment or progression of cerebellar atrophy on subsequent
scans obtained on MR systems and imaging protocols that
were also used before the change in cerebellar atrophy.
With respect to natalizumab pharmacovigilance using
MRI, the ability of MRI in prospectively identifying GCN
in the absence of PML lesions remains questionable [18,
20], whether similar to the diagnostic dilemma in asymp-
tomatic natalizumab-associated PML the detection of JCV
DNA in the CSF can support the clinical and/or MRI
diagnosis is unknown and needs to be investigated [27].
In conclusion, the identification of three probable GCN
cases in natalizumab-treated MS patients with PML
emphasizes the need for awareness of this combination or
coincidence of different JCV-related diseases. Cerebellar
symptoms in natalizumab-treated MS patients require early
and frequent assessment for cerebellar atrophy, and if
needed, JCV detection in CSF. In addition, assessment of
(the progression of) cerebellar atrophy in the treatment of
natalizumab-associated PML seems paramount.
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Table 3 Degree of cerebellar atrophy and presence of infratentorial PML lesions in the three suspected GCN cases
Atrophy grade
before Dx
Atrophy grade
at Dx
Atrophy grade
after Dx
Months after Dx
of scoring
‘‘Infratentorial PML’’
lesions present?
Cerebellar
symptoms
Patient 1 0 0 2 3 months No Yes
Patient 2 0 0 1 2.5 months No n/a
Patient 3 1 1 2 3 months Yes Yes
PML progressive multifocal leukoencephalopathy, Dx diagnosis of PML, n/a not available, four-grade cerebellar atrophy rating scale: grade 0: no
atrophy; grade 1: dilated sulci; grade 2: loss of volume; grade 3: end-stage atrophy
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